Fyodor is a growing Maryland corporation organized to develop and commercialize novel biotechnologies into simple medical diagnostics and biotherapeutics to serve the multi-billion dollar global health market in several emerging economies. Our corporate mission presents a unique social entrepreneurship model that allows the company and its investors to do well within the context of social good.
Fyodor Biotechnologies Corporation is a privately held, socially-responsible company focused on the research, development and manufacture of innovative diagnostic and biopharmaceutical products, first targeted to large emerging economies in Africa, Asia and South America.
Fyodor’s mission is to address certain urgent healthcare needs of people in target markets by developing and commercializing relevant and novel technologies capable of providing practical solutions to issues affecting patient care on a personal level, and economic development on a broader level.
Diseases such as malaria, sleeping sickness, meningitis and typhoid fever are leading causes of morbidities and deaths in most emerging economies around the world. Malaria is endemic in over 108 countries in Africa, Asia, South America, Mediterranean, and the Western Pacific. The most pronounced challenges in controlling these diseases is the limited availability of, and access to, accurate, rapid, point-of-care diagnostic tools and sustained effective treatment. To sustain the utility of any newer drugs and vaccines, diagnostic tools for monitoring the development of drug resistance in malaria is an important complement to an integrated approach. Our specific goal is to expand the availability and affordability of rapid diagnostics and pharmaceuticals against infectious diseases, with an initial focus on malaria.